ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RPRX vs UNH // OPERATING MARGIN

Royalty Pharma plc Class A Ordinary Shares (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RPRX 6 — UNH 9
▲ OPERATING MARGIN LEADER: RPRX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. UNH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RPRX UNH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 41.00% 88.57% -47.57 UNH /gross-margins <GO>
Return on Invested Capital (ROIC) 7.00% 11.47% -4.47 UNH /roic <GO>
EV/EBITDA & P/E Valuation 27.8x 16.4x +11.35 UNH /valuation <GO>
Free Cash Flow Yield 6.29% 6.48% -0.19 UNH /fcf-yield <GO>
Operating Margin ACTIVE 65.60% 4.82% +60.78 RPRX /operating-margins <GO>
Net Profit Margin 32.40% 3.14% +29.26 RPRX /net-margins <GO>
Revenue Growth (YoY) 5.10% 6.46% -1.36 UNH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.28% -2.28 UNH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.90 3.12 -0.22 UNH /balance-sheet <GO>
Piotroski F-Score Quality 8/9 7/9 +1.00 RPRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew 6.70% 6.74% -0.04 RPRX /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 76.7 56.0 +20.68 RPRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.94 0.33 +0.61 RPRX /macro-sensitivity <GO>
Forward P/E Multiple 45.8x 17.1x +28.71 UNH /forward-pe <GO>
Enterprise Scale & Market Cap $37.91B $364.66B -$326.75B UNH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RPRX REV UNH REV RPRX GROSS % UNH GROSS % RPRX FCF UNH FCF
FY 2025 $2.38B $447.57B 44.0% 88.7% $2.38B $16.07B
FY 2024 $2.26B $400.28B 44.0% 88.3% $2.67B $20.70B
FY 2023 $2.35B $371.62B 44.0% 89.6% $2.88B $25.68B
FY 2022 — $324.16B — 89.6% — $23.40B
FY 2021 — $287.60B — 89.2% — $19.89B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
UNH // BETA 0.33